A Pivotal Role of Cyclic AMP-Responsive Element Binding Protein in Tumor Progression

Rinat Abramovitch, Einat Tavor, Jasmine Jacob-Hirsch, Evelyne Zeira, Ninette Amariglio, Orit Pappo, Gideon Rechavi, Eithan Galun, Alik Honigman*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

138 Scopus citations


Tumor microenvironment controls the selection of malignant cells capable of surviving in stressful and hypoxic conditions. The transcription factor, cyclic AMP-responsive element binding (CREB) protein, activated by multiple extracellular signals, modulates cellular response by regulating the expression of a multitude of genes. Previously, we have demonstrated that two cystein residues, at the DNA binding domain of CREB, mediate activation of CREB-dependent gene expression at normoxia and hypoxia. The construction of a dominant-positive CREB mutant, insensitive to hypoxia cue (substitution of two cystein residues at position 300 and 310 with serine in the DNA binding domain) and of a dominant negative CREB mutant (addition of a mutation in serine 133), enabled a direct assessment, in vitro and in vivo, of the role of CREB in tumor progression. In this work, we demonstrate both in vitro and in vivo that CREB controls hepatocellular carcinoma growth, supports angiogenesis, and renders resistance to apoptosis. Along with the identification, by DNA microarray, of the CREB-regulated genes in normoxia and hypoxia, this work demonstrates for the first time that in parallel to other hypoxia responsive mechanisms, CREB plays an important role in hepatocellular carcinoma tumor progression.

Original languageAmerican English
Pages (from-to)1338-1346
Number of pages9
JournalCancer Research
Issue number4
StatePublished - 15 Feb 2004


Dive into the research topics of 'A Pivotal Role of Cyclic AMP-Responsive Element Binding Protein in Tumor Progression'. Together they form a unique fingerprint.

Cite this